This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The company’s main area of focus is cystic fibrosis (CF). The company’s lead marketed products are Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor), Symdeko/Symkevi (tezacaftor in combination with ivacaftor), Orkambi (lumacaftor in combination with ivacaftor) and Kalydeco (ivacaftor), which are collectively approved to treat the majority of the people with CF in North America, Europe and Australia. Trikafta, Vertex’s triple combination regimen, was approved by the FDA in October 2019 for the treatment of CF in people aged 12 years and older who have at least one F508del mutation. Kaftrio (brand name of Trikafta in EU) was approved in the European Union in August 2020. It is also being evaluated in younger patients in the United States. With approval of Trikafta, Vertex can address a significantly larger CF patient population — almost 90% of patients with CF — in the future. Meanwhile, Vertex is pursuing genetic therapies to address the remaining 10% of CF patients. While CF remains the main area of focus, Vertex is also developing treatments for sickle cell disease, thalassemia and pain management.
Incyte (INCY) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Incyte's (INCY) top line is likely to have been driven in the first quarter by the sales of its lead drug, Jakafi.
BD (BDX) Gears Up for Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Continued strength in BD's (BDX) Interventional segment is expected to have driven up Q2 sales.
Boston Scientific (BSX) Q1 Earnings Top, 2022 Revenue View Up
by Zacks Equity Research
Boston Scientific (BSX) registers a year-over-year improvement in organic sales, indicating a strong rebound in the legacy business from the pandemic mayhem.
Chemed's (CHE) Q1 Earnings Top Estimates, Margins Increase
by Zacks Equity Research
In Q1, Chemed's (CHE) VITAS revenue decline was primarily the result of a 4.1% decline in days of care.
Ecolab's (ECL) Q1 Earnings in Line, Revenues Beat Estimates
by Zacks Equity Research
Ecolab's (ECL) robust performance across all of its segments drives its Q1 sales despite business challenges.
Quidel (QDEL) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Quidel's (QDEL) first-quarter results are likely to reflect continued strength across its SARS-related products.
Novartis (NVS) Beats on Q1 Earnings, Sandoz Posts Growth
by Zacks Equity Research
Novartis (NVS) beats on earnings in the first quarter but sales lag expectations. Generic Sandoz business returns to growth.
Is a Beat Likely for AbbVie (ABBV) This Earnings Season?
by Zacks Equity Research
AbbVie's (ABBV) first-quarter results are expected to reflect the impact of strong demand for immunology drugs, aesthetics and cosmetics products. Investors are likely to focus on any update related to Humira LOE.
Novartis (NVS) Gets Positive CHMP Opinion on Lung Cancer Drug
by Zacks Equity Research
The CHMP gives a positive opinion on, and recommends approval for Novartis' (NVS) Tabrecta for treating patients with METex14 advanced non-small cell lung cancer.
Roche's (RHHBY) Q1 Sales Grow on COVID-19 Tests, New Drugs
by Zacks Equity Research
Roche (RHHBY) performance in the first quarter was encouraging, driven by demand for COVID-19 tests and contribution from newer drugs.
Glaxo (GSK) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Glaxo's (GSK) COVID-19 solutions, newer respiratory and HIV drugs are likely to have driven first-quarter sales. The performance of vaccines during Q1 remains to be seen.
Why bluebird bio (BLUE) Stock Plunged 60% Year to Date?
by Zacks Equity Research
With no stable stream of income, bluebird bio (BLUE) faces a severe cash crunch. Moreover, the FDA extending the review period of its two regulatory filings also adds fuel to this fire.
CRISPR (CRSP) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On CRISPR Therapeutics' (CRSP) Q1 earnings call, investors will look for updates on its pipeline candidates, especially its lead candidate CTX001.
Apellis (APLS) Thrives on Empaveli, Stiff Competition a Woe
by Zacks Equity Research
Apellis' (APLS) marketed drug, Empaveli, is approved for treating paroxysmal nocturnal hemoglobinuria. The drug's label expansion studies hold promise. Stiff competition remains an overhang.
4 Reasons to Add Deciphera (DCPH) Stock to Your Portfolio
by Zacks Equity Research
Deciphera's (DCPH) Qinlock, approved for treating advanced gastrointestinal stromal tumors, has seen strong uptake since approval. The recent restructuring initiative is saving costs.
Intercept (ICPT) Outperforms Industry in 3 Months: What Lies Ahead?
by Zacks Equity Research
Intercept (ICPT) lead drug Ocaliva holds ground amid challenges. A positive readout from the NASH studies will be a good boost for the stock in the year ahead.
The Zacks Analyst Blog Highlights Johnson & Johnson, Eli Lilly, Vertex Pharmaceuticals and Deciphera Pharmaceuticals
by Zacks Equity Research
Johnson & Johnson, Eli Lilly, Vertex Pharmaceuticals and Deciphera Pharmaceuticals have been included in this Analyst Blog.
Vertex Pharmaceuticals (VRTX) Stock Moves -1.26%: What You Should Know
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $281.71, moving -1.26% from the previous trading session.
What to Expect From Centene (CNC) this Earnings Season?
by Zacks Equity Research
Centene's (CNC) first-quarter results are likely to reflect growing revenues attributable to a rise in premiums and membership, partly offset by lower investment income.
J&J Sets in Motion Drug/Biotech Q1 Earnings: 3 Stocks to Buy
by Kinjel Shah
Investors typically look at J&J's (JNJ) results to gauge how the rest of the drug sector will fare.
Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $285.30, marking a +0.98% move from the previous day.
Will Vertex (VRTX) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Teva's (TEVA) Schizophrenia Drug Gets CRL From the FDA
by Zacks Equity Research
Teva Pharmaceuticals (TEVA) and partner MedinCell's new drug application for risperidone to treat schizophrenia faces rejection from the FDA.
Moderna (MRNA) Posts Upbeat Data on Bivalent COVID Booster Jab
by Zacks Equity Research
Moderna's (MRNA) bivalent COVID booster candidate creates superior neutralizing antibodies compared to its currently authorized COVID vaccine mRNA-1273's booster dose against all variants of concern.
AstraZeneca's (AZN) Enhertu sBLA Receives FDA Priority Tag
by Zacks Equity Research
FDA grants priority review to AstraZeneca (AZN) and Daiichi Sankyo's sBLA seeking approval of Enhertu for previously treated HER2-mutant metastatic non-small cell lung cancer (NSCLC).